Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on the stock. HC Wainwright reiterated a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a research note on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Barclays decreased their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd. Finally, Mizuho cut their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

RVNC opened at $3.65 on Friday. The firm has a 50-day moving average price of $3.49 and a 200-day moving average price of $4.52. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.56. The company has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90.

Institutional Trading of Revance Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Natixis purchased a new position in shares of Revance Therapeutics during the fourth quarter worth about $31,000. Two Sigma Securities LLC purchased a new stake in Revance Therapeutics in the fourth quarter valued at approximately $35,000. Alpine Global Management LLC bought a new stake in Revance Therapeutics during the fourth quarter valued at approximately $37,000. FORA Capital LLC purchased a new position in Revance Therapeutics in the 3rd quarter worth approximately $54,000. Finally, RPO LLC bought a new position in shares of Revance Therapeutics in the 4th quarter worth $55,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.